Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer

Inclusion Criteria: * Histologically proven renal cell cancer with metastases; pathology from either primary or metastatic tumor; no histologic subtype restriction * Evidence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 or evaluable disease * Eastern Cooperative Oncology Group (ECOG) performance score 0 to 1 * Hemoglobin \>= 9 gram/dL * Common Terminology Criteria for Adverse Events (CTCAE) fatigue levels pre-treatment \< 2 * Signed and dated informed consent Exclusion Criteria: * Greater than 2 previous systemic treatments for RCC * Heart failure, New York Heart Association (NYHA) class 3 and 4 * Unstable angina (defined as ongoing use of nitrates or cardiac ischemia in the prior 6 months) * Arrhythmia uncontrolled by medication * Hypertension (\> 160/90 mmHg) not controlled with medical management * Brain metastases or previous cranial radiation, leptomeningeal cancer * Surgery within 2 weeks of study entrance * History of stroke, myasthenia gravis, multiple sclerosis, polyneuropathy * Pregnancy or breast feeding * Central-nervous system active medications, intake or withdrawal of which lowers seizure threshold (determination made in consultation with study's responsible treating physician) * Any history of epilepsy, convulsion or seizure * Medication-resistant epilepsy in a first-degree relative * Cochlear implants or internal pulse generators or cardiac pacemakers or intracardiac lines * Metallic implants in the vicinity of discharging coil in the head or cervical spine * Unexplained fainting spells/syncope or multiple concussions * History of severe head trauma (followed by loss of consciousness) * Implanted brain or spinal cord electrodes/stimulation * Medication infusion device * Frequent/severe headaches or severe migraines * Past or current medical history of diagnosed or undiagnosed tinnitus